Biotech halts cell therapy development after 2 patient deaths
Artiva Biotherapeutics is discontinuing development of its AlloNK cell therapy and cutting its workforce by approximately 94% after longer-term clinical data and two recent patient deaths. The company said longer-term follow-up of AlloNK did not show the level of durability of clinical response needed to support continued development, according to an Oct. 27 news release. […] The post Biotech halts cell therapy development after 2 patient deaths appeared first on Becker's Hospital Rev...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.